Netcare Limited Overview
Netcare is South Africa's largest private hospital operator. In the Competition Commission's Health Market Inquiry, it held about 31% of private hospital beds and 33% of admissions on 2016 data. Its operations are entirely in South Africa. They form an integrated ecosystem of 49 acute hospitals, the country's largest private mental health network (Netcare Akeso), pre-hospital emergency services (Netcare 911), cancer care, primary and occupational healthcare (Netcare Medicross, Netcare Occupational Health), prepaid and gap-cover products (NetcarePlus), point-of-care diagnostics, nursing and paramedic education, and an equity-accounted renal dialysis joint venture (National Renal Care). After leaving the UK in 2018, the group has pursued a ten-year, three-phase strategy launched in 2018: digitisation, data/AI-driven care, and person-centred care. It completed an ecosystem-wide electronic medical record in 2024. Since FY2022 it has expanded EBITDA margins every year, and it returns surplus cash through dividends (50–70% of adjusted HEPS) and a buyback programme that started in September 2023. Founder-CEO Dr Richard Friedland retires on 31 December 2026 and will be succeeded by Melanie Da Costa.
Company's own description. In its FY2024 annual financial statements, Netcare describes itself as a leading provider of private healthcare services in South Africa. It provides acute services across a national hospital network and is the market leader in acute mental health. It also provides emergency, cancer care, diagnostic support, primary care and renal care services, plus occupational health and wellness. It aims to widen access to affordable care through NetcarePlus products and vouchers, and Netcare Education trains nurses and emergency medical personnel (S3, FY2024). The directors' report describes Netcare Limited as an investment holding company. Through subsidiaries, joint arrangements and associates in Southern Africa, it runs a private hospital group offering general, emergency and specialised care, with ancillary primary care, administration and logistics businesses (S3, FY2024).
Reporting structure. Netcare reports two segments:
-
Hospital and emergency services. This is about 97.5% of FY2025 revenue. It is split into:
-
Hospital and pharmacy operations: the acute hospital network, day clinics and institutional pharmacies.
-
Non-acute services: Netcare 911, Netcare Akeso mental health clinics, Netcare Cancer Care, Netcare Diagnostics, NetcarePlus product and voucher sales, and (from June 2025) Quro Medical hospital-at-home.
-
-
Primary Care. This is about 2.5% of FY2025 revenue. It covers Netcare Medicross primary healthcare and dental centres, employee health and wellness (Netcare Occupational Health), and administrative services to medical and dental practices.
Revenue model. Netcare does not report revenue split by product versus service. Its revenue recognition notes (S3, FY2024) show the following mechanics:
Hospital and pharmacy (about 90% of revenue): ward, theatre and equipment fees, plus pharmaceuticals and consumables used during treatment. Revenue is recognised over the patient's stay. Most is paid by third-party medical schemes under annually negotiated tariffs, including lower-tariff Designated Service Provider (DSP) and restricted-network contracts. Cost of goods sold was R6,965m in FY2025, or 26.4% of revenue. This shows that dispensed medicines and consumables are a large part of billed value.
Emergency services: recognised once a contract exists with the patient or next of kin. In an emergency, no contract exists at the time of service.
Mental health: contract-based per-patient revenue.
NetcarePlus: prepaid vouchers and procedures are recognised when redeemed. Gap cover products are underwritten by a third-party insurer (Hollard).
Netcare Diagnostics: fees for administrative and logistics services to a third-party pathology practice.
Cancer care: a substantial part is operating-lease rental of oncology assets.
Primary Care: practice administration fees and per-visit treatment revenue. Occupational health revenue is earned under corporate contracts.
Other income: property rental income from doctors' rooms, pharmacies and retail tenants on hospital sites. This was R454m in FY2025 (S2, segment note) and R435m in FY2024.
There is no subscription or licensing model of significance. NetcarePlus prepaid products and GapCare have subscription-like features but are not separately sized.
Value-chain position. Netcare is a provider. It owns most of its hospital real estate. Land and buildings had a carrying value of R11.2bn and an independent fair value of R22.2bn at 30 September 2024 (S3, FY2024). It does not employ most specialists. Under South African rules, specialists are independent practitioners who hold admission rights. Netcare employs nurses, pharmacists, paramedics and support staff. Upstream, it buys pharmaceuticals, consumables and medical equipment. Downstream, it is paid mainly by medical schemes (funders), with some out-of-pocket, corporate (occupational health) and public-sector or uninsured (NetcarePlus) revenue.
Customer types and end markets.
-
Insured private patients (medical scheme beneficiaries). This is the dominant group, in a market of about 9.17 million scheme beneficiaries in 2024.
-
Medical schemes and administrators as contracting counterparties (for example DSP networks).
-
Employers (occupational health contracts).
-
Employed but uninsured households (NetcarePlus).
-
Government, through emergency services and historic public-private partnerships. The Lesotho PPP was terminated in August 2021.
-
Independent specialists and GPs who choose where to admit patients.
Independent characterisation. Netcare is a mature, high-fixed-cost, volume-sensitive hospital operator in a concentrated but slow-growing insured market. Its earnings growth since FY2022 has come mostly from margin expansion and per-share accretion, not from volume:
-
Total paid patient days (PPD) grew only 0.7% in FY2025 and about 1.6% in FY2026.
-
Normalised EBITDA margin rose from 15.2% (FY2021) to 18.6% (FY2025), helped by digitisation savings and lower strategic and diesel costs.
-
About 10.4% of shares were repurchased between September 2023 and FY2025.
Its strategic distinctiveness rests on four things: an integrated multi-service ecosystem, the first fully implemented ecosystem-wide EMR in Africa, the only four private Level 1 trauma centres accredited by the Trauma Society of South Africa, and leadership in private mental health.
Strategy
Stated corporate strategy (paraphrased from S1/S2). Netcare is executing a ten-year strategy launched in 2018. Its stated aim is a lasting competitive advantage and becoming the provider of choice for patients, doctors and funders. The strategy is built around three global healthcare megatrends (customer centricity, digitisation, and data/AI-driven care) applied across Netcare's integrated ecosystem. Management describes the group as being in the "latter stages" of the journey. There are three overlapping phases:
-
Digitally enabled: completed in 2024 with full EMR rollout. All operating costs are now in the hospital cost base.
-
Data and AI driven: "well advanced". About 53GB of clinical data is generated daily. Real-time analytics support standardised clinical pathways. Examples include a predictive ICU sepsis algorithm and a patient-facing large language model (both described as firsts in Africa), plus planned generative AI tools for clinicians and research.
-
Person-centred health and care: gives patients direct access to their health records and deepens engagement.
Strategic initiatives, last 24 months (Oct 2024 – Oct 2026)
Cost programmes. No named group-wide cost programme with a rand target was disclosed beyond the digitisation savings and environmental savings above. Strategic project operating costs were R23m in H1 FY2026 (R17m attributable to NetcarePlus), and strategic capex was R17m.
Management guidance (FY2026; S2, May 2026):
-
Revenue growth 4.0%–4.8% (originally 4%–5%, S22).
-
Acute PPD growth 0.3%–0.8% (originally 0.8%–1.5%).
-
Total PPD growth 1.1%–1.6% (originally 1.8%–2.4%). Business Day reported 1.1%–1.8%; the primary interim document states 1.1%–1.6% (S8 vs S2).
-
Further EBITDA margin expansion, higher earnings and higher ROIC.
-
Capex about R1.9bn, of which R566m is expansionary.
-
Dividends of 50%–70% of adjusted HEPS; buybacks to continue to be considered.
Medium-term financial targets. Netcare does not publish explicit multi-year revenue, margin or ROIC targets. Debt policy thresholds are net debt/EBITDA below 2.75x and EBITDA/net interest above 4.0x.
Products & Services
The company does not publish a priced product catalogue. Hospital pricing is set through annual tariff negotiations with medical schemes and is not disclosed. Facility counts below come from the FY2023 results presentation, the latest primary-source asset count found. A later third-party description and subsequent company commissioning announcements are noted where they differ.
Hospital and pharmacy operations (H&ES segment)
| Offering | Description / capabilities | Target customer | Latest data point | Pricing model | Source |
|---|---|---|---|---|---|
| Netcare Hospitals (acute network) | 49 acute hospitals with 9,903 beds (FY2023). A later third-party count shows 9,827 beds. Medical and surgical admissions; surgical cases bring in over 70% of revenue and about 51% of PPD. ICU and high-care capacity is used above 2019 levels. | Medical scheme members, referring specialists, funders (DSP networks) | FY2025: acute occupancy 65.0%; average length of stay 4.5 days. FY2026: about 66% occupancy expected. | Per-diem ward, theatre and equipment fees plus medicines, under negotiated scheme tariffs | S5; S23; S1; S8 |
| Flagship trauma centres | Netcare operates the only four Level 1 trauma facilities in the private sector accredited by the Trauma Society of South Africa. Netcare Christiaan Barnard Memorial Hospital received Level One accreditation (FY2023). Netcare Milpark Hospital runs a dedicated trauma programme. | Trauma patients, EMS, funders | H1 FY2026 | Tariff-based | S2; S5 |
| Stroke centres | Two Netcare hospitals accredited by the World Stroke Organization in FY2025, a first in Africa (34 facilities worldwide) | Stroke patients | FY2025 | Tariff-based | S1 |
| Netcare Alberton Hospital | New 427-bed hospital commissioned April 2022; traded above 80% occupancy in FY2022 | East Rand / Gauteng catchment | 2,022 | Tariff-based | S4 |
| Netcare Pretoria East Hospital | 358-bed hospital; fire in Dec 2024; excluded from PPD metrics | Tshwane catchment | FY2025–26 | Tariff-based | S1; S2 |
| Netcare Blaauwberg Hospital | Certified as the first Green Hospital in Africa (reported May 2026) | Cape Town catchment | H1 FY2026 | Tariff-based | S2 |
| Day clinics | 12 day clinics (FY2023); 11 in a later third-party count | Day-case surgery | FY2023 | Tariff / procedure-based | S5; S23 |
| Institutional pharmacies | In-hospital medicine supply, management and dispensing | Inpatients | Ongoing | Single exit price plus dispensing fees (regulated; Netcare-specific figures not disclosed) | S23 |
| Bed optimisation programme | 29 beds converted to higher-acuity disciplines and 51 new beds added in existing hospitals (H1 FY2026); about 19–20 further beds in H2 FY2026 | — | FY2026 | — | S2; S8 |
Non-acute services (H&ES segment)
| Offering | Description / capabilities | Target customer | Latest data point | Pricing model | Source |
|---|---|---|---|---|---|
| Netcare 911 | Pre-hospital emergency medical services: 92 sites (FY2023); a later third-party count gives 93 bases, 240 ambulances and response vehicles, 4 helicopter ambulances, 5 fixed-wing aircraft and a National Emergency Operations Centre. Emergency line 082 911 and access via the Netcare App. | Public, scheme members, corporates | FY2023 / later | Fee-for-service billed after contracting | S5; S23 |
| Netcare Akeso | Largest private mental health network: 14 hospitals and 1,007 beds (FY2023), plus Polokwane (87 beds, March 2026). Pipeline: Alberlito (80 beds, March 2027) and Montana (88 beds, now August 2027, previously October 2026). Includes dialectical behaviour therapy programmes. | Psychiatric and substance-use patients | Mental health occupancy 70.0% (H1 FY2026); about 72.7% expected for FY2026 | Per-diem / programme tariffs | S5; S2; S8 |
| Netcare Cancer Care | 8 radiation treatment centres and 8 haematology centres (FY2023); 9 radiation centres in a later count. Radiosurgery, radiotherapy, chemotherapy, bone-marrow transplant and robotic-assisted surgery. Aria oncology EMR. | Oncology patients and oncologists | FY2023 / later | Part of revenue is operating-lease rental of oncology assets | S5; S1; S3 |
| NetcarePlus | Products for the employed but under-insured: prepaid healthcare vouchers; prepaid procedures (general, gynaecological, orthopaedic, ENT); dental vouchers; GapCare (three gap-cover products underwritten by Hollard); accident and trauma cover; primary care insurance; baby care. Sold through retail, financial-services and broker channels. | Uninsured / under-insured households; scheme members on network plans | FY2025: strong sales growth in retail and corporate channels. H1 FY2026: R17m of strategic operating costs. | Prepaid (revenue recognised at redemption); insurance premiums with a third-party underwriter | S4; S1; S2; S3 |
| Netcare Diagnostics | Point-of-care testing (192 devices, FY2023; 130 blood-gas analysers in ICUs and high-care units, rolled out in 2022). Administrative and logistics support to Dr Esihle Nomlomo Inc, a Black female-owned pathology practice. Pathology available at 24 Medicross facilities, 8 with point-of-care testing (H1 FY2025). | Inpatients, Medicross patients | H1 FY2025 | Service fees to the pathology practice | S4; S5; S10 |
| Quro Medical (55.88%) | Tech-enabled "hospital at home": remote clinical-grade monitoring of acutely ill patients at home | Funders, patients | Acquired June 2025; R14m revenue and R1m operating loss in its first months | Funder reimbursement contracts | S16 |
| Wearable continuous monitoring | Pilot of clinical-grade wearables in general wards at a flagship facility. Monitors heart rate, respiratory rate, core temperature, oxygen saturation and continuous blood pressure, integrated with the EMR. Group-wide rollout depends on pilot results. | Inpatients | Announced Nov 2025; pilot under way H1 FY2026 | Embedded in the hospital cost base (no separate pricing disclosed) | S1; S2 |
| Netcare Education | Faculty of Nursing and Ancillary Healthcare; Faculty of Emergency and Critical Care. A leading private trainer of nursing and emergency medical personnel. | Students, Netcare workforce pipeline | Ongoing | Tuition / internal | S1; S19 |
| Digital platforms | CareOn EMR (hospitals, emergency), Aria (cancer), NephrOn (renal), Netcare App, appointmed. Analytics platform processing about 53GB of clinical data daily. Large language model for patient engagement (first hospital group in Africa to deploy one). Predictive sepsis algorithm in ICU. | Clinicians, patients, funders | FY2025–H1 FY2026 | Internal enabler | S1; S2 |
Primary Care segment
| Offering | Description / capabilities | Target customer | Latest data point | Pricing model | Source |
|---|---|---|---|---|---|
| Netcare Medicross | 63 family medical and dental centres (FY2023), some with day theatres | Families, scheme members, cash patients | FY2023 | Per visit; administration fees to practices | S5; S3 |
| Netcare Occupational Health | Employee health and wellness, travel health, risk management. 33 contracts and 1,135 clients (FY2023); 47 contracts in a later third-party count. A large contract was not renewed in May 2025; two new contracts were added in H1 FY2026. | Employers | H1 FY2026 | Contract-based | S5; S1; S2; S23 |
| Practice administration services | Administrative services to medical and dental practices | Independent practitioners | Ongoing | Fees | S3 |
| Prime Cure | Medical centres; count in secondary sources only (5) | Lower-income insured | — | — | S19 (secondary) |
Equity-accounted joint venture
| Offering | Description | Latest data point | Source |
|---|---|---|---|
| National Renal Care (NRC) | Renal dialysis: 73 facilities and 996 stations (FY2023); 75 facilities and 1,013 stations in a later third-party count. NephrOn EMR. | H1 FY2026: JV and associate earnings +50% to R45m, driven by NRC | S5; S23; S2 |
Financial Narrative
All figures are ZAR millions unless stated. Sources: FY2021–FY2022 from S4; FY2023–FY2024 from S3; FY2025 from S2 (FY2025 comparatives) and S1. "Normalised" figures are company non-IFRS measures that exclude exceptional items.
Income statement
Notes:
-
FY2021 normalised revenue (R21,005m) and normalised EBITDA exclude Lesotho PPP-related items.
-
FY2025 reported EBITDA is higher than normalised because it includes a R62m net insurance gain on the Pretoria East claim. Other FY2025 exceptional items: a R61m impairment of an investment in an associate and a R2m property impairment.
-
FY2024 normalised EBITDA was R4,530m. The FY2024 results release said normalised EBITDA rose 10.1% from R4,115m.
Margins and growth (analyst-calculated unless marked "co.")
CAGRs, FY2021–FY2025 (four years):
-
Reported revenue: 5.6% a year (5.8% on the normalised FY2021 base).
-
Normalised EBITDA: 11.4% a year.
-
Adjusted HEPS: 19.4% a year.
-
Dividend per share: 25.7% a year (34c to 85c).
The FY2023 EBITDA margin of 17.4% is derived; the FY2023 presentation reported a 120bp improvement.
Balance sheet (at 30 September)
Balance sheet at 31 March 2026:
-
Total assets R29,383m; cash R1,985m.
-
Borrowings R8,092m (short-term R1,354m; long-term R6,738m).
-
Net debt excluding leases R6,107m; lease liabilities R5,569m.
-
Total equity R10,938m.
Debt is all unsecured: promissory notes and commercial paper of R7,033m and bank loans of R1,054m. No property, plant or equipment is pledged as security (S3, FY2024). On 24 April 2026 Netcare raised R800m of new 3-year and 5-year term loans at about 7.7%.
Cash flow
Notes:
-
Analyst FCF = cash generated from operations, less interest paid on debt, less interest paid on leases, less tax paid, less capex, less lease principal.
-
Netcare presents dividends paid inside operating cash flows.
-
The FY2022 treasury share purchases of R29m were for incentive schemes. The buyback programme began in September 2023.
-
Netcare reported R1.8bn returned to shareholders through dividends and buybacks in FY2025.
-
FY2026: R1.04bn was spent to repurchase 60.2m shares. H1 FY2026: dividends of R626m (ordinary and preference) and buybacks of R351m.
Ratios
Notes:
-
The company's EBITDA/net interest cover was 4.3x in H1 FY2025 and 4.6x in H1 FY2026.
-
A full cash conversion cycle cannot be calculated reliably from disclosed balances, because trade and other payables include accruals. Netcare does not publish one, so it is not publicly disclosed. Inventory was R520m at FY2025 against cost of goods sold of R6,965m, about 27 days.
-
The FY2023 presentation states debt policy thresholds of net debt/EBITDA below 2.75x and EBITDA/net interest above 4.0x.
Commentary on trends, inflections and drivers
Recovery phase (FY2021–FY2023). FY2021 was distorted by the second and third COVID-19 waves (Beta and Delta). Netcare estimated about R521m of COVID-specific costs in FY2021. Revenue fell 2.6% in FY2021, but EBITDA rose 33.3% on cost control. The fourth wave (Omicron) in early FY2022 was milder, and activity normalised from late January 2022. Total patient days rose 5.4% in FY2022, and acute occupancy climbed from 56.2% to 59.3%. FY2023 brought the main revenue step-up, +9.5% to R23,699m. Normalised EBITDA rose 17.7% despite heavy load-shedding and diesel costs.
Margin-led phase (FY2024–FY2026). From FY2024, volumes have been nearly flat:
- Total PPD: +0.3% expected for FY2024, +0.7% in FY2025, about +1.6% in FY2026.
Margins and per-share returns kept improving. The drivers are:
-
Pricing and mix: acute revenue per PPD +6.0% in FY2024 and +4.1% in H1 FY2026, even as lower-tariff DSP volume grew.
-
Digitisation dividend: cumulative gross cash savings and cost avoidance of R705m since FY2022, against total investment of R670m (R320m capex plus R350m implementation opex). The expected IRR was raised from above 25% (FY2025, S1) to above 30% (H1 FY2026, S2).
-
Falling strategic project costs: R249m in FY2022, R131m in FY2024, R56m in FY2025.
-
Energy savings: lower diesel use and energy-efficiency savings (Phase 1 environmental programme: R1.5bn cumulative savings, IRR about 40%, S2).
-
Lower cost of debt: 8.9% in H1 FY2025 and 8.2% in H1 FY2026.
-
Buybacks: weighted shares fell from 1,330m (FY2023) to 1,224m (FY2025) and 1,191m (H1 FY2026). This is why adjusted HEPS (+20.7% in FY2025) grew much faster than profit after tax (+17.0%).
Cash. Cash generated from operations jumped 25% to R5,468m in FY2025, with conversion of 111.3%. H1 FY2026 cash generation was lower at R1,653m (H1 FY2025: R2,069m) because of working-capital outflows: trade payables fell from R4,263m to R3,731m and receivables rose to R4,321m. This seasonal or timing outflow, together with dividends and buybacks, lifted net debt to R6.1bn at March 2026. FY2026 cash conversion is a monitorable.
Leverage. Net debt excluding leases has stayed between R4.9bn and R6.1bn since FY2022. Bank-debt leverage remains low at 1.1–1.2x. Including R5.6bn of IFRS 16 lease liabilities, total debt-like obligations were about R11.7bn at March 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment / metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hospital & pharmacy operations revenue (ZAR Mn) | 19,465 | 19,733 | 21,472 | 22,807 | 23,648 |
Non-acute services revenue (ZAR Mn) | 1,152 | 1,291 | 1,578 | 1,699 | 2,047 |
Hospital & emergency services revenue (ZAR Mn) | 20,617 | 21,024 | 23,050 | 24,506 | 25,695 |
Primary Care revenue (ZAR Mn) | 595 | 634 | 663 | 712 | 662 |
Inter-segment elimination (ZAR Mn) | -12 | -22 | -14 | -16 | -13 |
Group revenue (ZAR Mn) | 21,200 | 21,636 | 23,699 | 25,202 | 26,344 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment / metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hospital & pharmacy EBITDA (ZAR Mn) | 3,040 | 3,211 | 3,661 | 4,228 | 4,451 |
Non-acute services EBITDA (ZAR Mn) | 80 | 111 | 168 | 115 | 315 |
H&ES EBITDA (ZAR Mn) | 3,120 | 3,322 | 3,829 | 4,343 | 4,766 |
Primary Care EBITDA (ZAR Mn) | 124 | 163 | 161 | 148 | 162 |
Hospital & pharmacy operating profit (ZAR Mn) | 2,144 | 2,282 | 2,615 | 3,161 | 3,370 |
Non-acute services operating profit (ZAR Mn) | -104 | -72 | 26 | -63 | 126 |
H&ES operating profit (ZAR Mn) | 2,040 | 2,210 | 2,641 | 3,098 | 3,496 |
Primary Care operating profit (ZAR Mn) | 36 | 72 | 75 | 61 | 79 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hospital & pharmacy EBITDA margin (%) | 15.6 | 16.3 | 17.1 | 18.5 | 18.8 |
Non-acute services EBITDA margin (%) | 6.9 | 8.6 | 10.6 | 6.8 | 15.4 |
H&ES EBITDA margin (%) | 15.1 | 15.8 | 16.6 | 17.7 | 18.5 |
Primary Care EBITDA margin (%) | 20.8 | 25.7 | 24.3 | 20.8 | 24.5 |
H&ES revenue growth YoY (%) | — | 2.0 | 9.6 | 6.3 | 4.9 |
Primary Care revenue growth YoY (%) | — | 6.6 | 4.6 | 7.4 | -7.0 |
H&ES share of group revenue (%) | 97.3 | 97.2 | 97.3 | 97.2 | 97.5 |
Primary Care share of group revenue (%) | 2.8 | 2.9 | 2.8 | 2.8 | 2.5 |
Segment Margins & Growth (%)
| Metric | H1 FY2025 | H1 FY2026 | Change (%) |
|---|---|---|---|
Hospital & pharmacy revenue | 11,416 | 11,921 | 4.4 |
Non-acute services revenue | 931 | 1,062 | 14.1 |
H&ES revenue | 12,347 | 12,983 | 5.2 |
H&ES normalised EBITDA | 2,266 | 2,429 | 7.2 |
H&ES normalised EBITDA margin (%) | 18.4 | 18.7 | 0.3 pts |
H&ES operating profit | 1,624 | 1,757 | 8.2 |
Primary Care revenue | 337 | 303 | -10.1 |
Primary Care EBITDA | 81 | 72 | -11.1 |
Primary Care operating profit | 39 | 29 | -25.6 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue, reported (ZAR Mn) | 21,200 | 21,636 | 23,699 | 25,202 | 26,344 |
Revenue, company-normalised (ZAR Mn) | 21,005 | 21,636 | 23,699 | 25,202 | 26,344 |
Gross profit (ZAR Mn) | 10,452 | 10,551 | 11,762 | 12,456 | 13,094 |
Operating profit, reported (ZAR Mn) | 2,076 | 2,282 | 2,716 | 3,159 | 3,575 |
Operating profit, normalised (ZAR Mn) | 2,025 | 2,293 | — | 3,198 | 3,559 |
EBITDA, reported segment total (ZAR Mn) | 3,244 | 3,485 | 3,990 | 4,491 | 4,928 |
EBITDA, normalised (ZAR Mn) | 3,193 | 3,496 | 4,115 | 4,530 | 4,912 |
Finance costs (ZAR Mn) | 903 | 885 | 1,064 | 1,269 | 1,218 |
Profit before tax (ZAR Mn) | 1,176 | 1,534 | 1,807 | 2,138 | 2,523 |
Taxation (ZAR Mn) | 416 | 484 | 471 | 591 | 713 |
Profit for the year (ZAR Mn) | 760 | 1,050 | 1,336 | 1,547 | 1,810 |
Profit attributable to owners of parent (ZAR Mn) | 730 | 975 | 1,271 | 1,436 | 1,681 |
Basic EPS (ZAR cents) | 54.6 | 72.3 | 94.5 | 110.4 | 135.3 |
Diluted EPS (ZAR cents) | 54.3 | 71.7 | 93.5 | 108.9 | 132.9 |
HEPS (ZAR cents) | 61.5 | 74.0 | 101.0 | 113.0 | 133.7 |
Adjusted HEPS (ZAR cents) | 67.4 | 83.2 | 105.7 | 113.7 | 137.2 |
Dividend per share, declared (ZAR cents) | 34.0 | 50.0 | 65.0 | 70.0 | 85.0 |
Weighted average shares (millions) | 1,336 | 1,338 | 1,330 | 1,279 | 1,224 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 49.3 | 48.8 | 49.6 | 49.4 | 49.7 |
Operating margin, reported (%) | 9.8 | 10.5 | 11.5 | 12.5 | 13.6 |
Normalised EBITDA margin, co. (%) | 15.2 | 16.2 | 17.4 | 18.0 | 18.6 |
Net margin, profit for year (%) | 3.6 | 4.9 | 5.6 | 6.1 | 6.9 |
Revenue growth YoY, reported (%) | — | 2.1 | 9.5 | 6.3 | 4.5 |
Normalised EBITDA growth YoY (%) | — | 9.5 | 17.7 | 10.1 | 8.4 |
Adjusted HEPS growth YoY (%) | 107.4 | 23.4 | 27.0 | 7.6 | 20.7 |
Effective tax rate (%) | 35.4 | 31.6 | 26.1 | 27.6 | 28.3 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (ZAR Mn) | 25,621 | 26,270 | 27,803 | 28,391 | 29,225 |
Property, plant & equipment (ZAR Mn) | 12,915 | 13,469 | 13,887 | 14,413 | 15,009 |
Right-of-use assets (ZAR Mn) | 3,600 | 3,770 | 4,073 | 4,418 | 4,308 |
Goodwill + intangible assets (ZAR Mn) | 1,806 | 1,843 | 1,873 | 1,920 | 2,132 |
Cash & cash equivalents (ZAR Mn) | 1,456 | 1,499 | 2,279 | 1,802 | 1,889 |
Short-term debt (ZAR Mn) | 1,851 | 1,105 | 1,249 | 1,603 | 562 |
Long-term debt (ZAR Mn) | 4,936 | 5,265 | 6,057 | 5,505 | 6,805 |
Total borrowings (ZAR Mn) | 6,787 | 6,370 | 7,306 | 7,108 | 7,367 |
Net debt excl. IFRS 16 leases (ZAR Mn) | 5,331 | 4,875 | 5,028 | 5,306 | 5,478 |
Lease liabilities, total (ZAR Mn) | 4,096 | 4,488 | 4,992 | 5,541 | 5,598 |
Total shareholders' equity (ZAR Mn) | 10,589 | 10,944 | 11,041 | 10,972 | 10,988 |
Equity attributable to owners of parent (ZAR Mn) | 9,933 | 10,246 | 10,376 | 10,289 | 10,227 |
Treasury shares, carrying (ZAR Mn) | 3,557 | 3,504 | 3,926 | 4,306 | 4,396 |
Working capital, current assets less current liabilities (ZAR Mn) | -27 | 157 | 825 | 119 | 857 |
Dividends & Capital Returns and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash generated from operations (ZAR Mn) | 3,794 | 3,950 | 4,135 | 4,374 | 5,468 |
Net cash from operating activities, after interest, tax and dividends as presented (ZAR Mn) | 2,305 | 1,884 | 1,880 | 1,869 | 2,447 |
Capex: PPE and intangible payments (ZAR Mn) | 1,144 | 1,396 | 1,507 | 1,519 | 1,630 |
Lease principal repaid (ZAR Mn) | 170 | 177 | 226 | 258 | 301 |
Analyst free cash flow (ZAR Mn) | 1,050 | 1,110 | 1,058 | 1,062 | 1,603 |
Ordinary dividends paid to owners of parent (ZAR Mn) | 0 | 728 | 808 | 850 | 957 |
Preference dividends paid (ZAR Mn) | 39 | 38 | 50 | 63 | 62 |
Treasury share purchases, incl. buybacks (ZAR Mn) | 0 | 29 | 510 | 722 | 855 |
Cash conversion ratio, co. (%) | 118.8 | 113.0 | 100.5 | 96.5 | 111.3 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, attributable profit / closing attributable equity (%) | 7.3 | 9.5 | 12.2 | 14.0 | 16.4 |
ROA, profit for year / total assets (%) | 3.0 | 4.0 | 4.8 | 5.4 | 6.2 |
ROIC, co.-reported (%) | 7.9 | 8.8 | — | 11.7 | 12.6 |
Current ratio (x) | 1.00 | 1.03 | 1.15 | 1.02 | 1.15 |
Gross debt / total equity (x) | 0.64 | 0.58 | 0.66 | 0.65 | 0.67 |
Net debt excl. leases / EBITDA, co. (x) | 1.7 | 1.4 | 1.2 | 1.2 | 1.1 |
Interest cover, operating profit / total finance costs incl. leases (x) | 2.3 | 2.6 | 2.6 | 2.5 | 2.9 |
EBITDA / net interest, co. bank-debt basis (x) | 4.1 | 4.5 | 4.5 | — | — |
Asset turnover, revenue / total assets (x) | 0.83 | 0.82 | 0.85 | 0.89 | 0.90 |
Trade receivable days, receivables / revenue × 365 | 56.0 | 55.5 | 54.6 | 57.1 | 56.0 |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
South Africa / Southern Africa revenue (ZAR Mn) | 21,200 | 21,636 | 23,699 | 25,202 | 26,344 |
Revenue growth YoY (%) | — | 2.1 | 9.5 | 6.3 | 4.5 |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Share price at 30 Sep (ZAR cents) | 1,620 | 1,372 | 1,350 | 1,541 | 1,420 |
Dividend per share declared (ZAR cents) | 34 | 50 | 65 | 70 | 85 |
Dividend payout, % of adjusted HEPS | 50.4 | 60.1 | 61.5 | 61.6 | 62.0 |
Treasury share purchases (ZAR Mn) | 0 | 29 | 510 | 722 | 855 |
Net debt excl. leases (ZAR Mn) | 5,331 | 4,875 | 5,028 | 5,306 | 5,478 |
Valuation Multiples
| Multiple | Netcare | Basis |
|---|---|---|
Market capitalisation | About R22.4bn | 1,166m × R19.22 |
P/E on FY2025 HEPS | 14.4x | 1922 / 133.7c |
P/E on trailing adjusted HEPS (150.1c) | 12.8x | — |
EV (including lease liabilities, preference shares, NCI) | About R34.9bn | Market cap + R6.1bn net debt + R5.6bn leases + R0.64bn preference + R0.14bn NCI |
EV / trailing normalised EBITDA (R5,066m) | 6.9x | Consistent with Halo's 6.9x (23 Jun 2026) |
EV / trailing revenue (R26,948m) | 1.3x | — |
P/B (equity attributable R10,155m) | 2.2x | — |
Trailing dividend yield (49c + 44c) | 4.8% | — |
Bucket Details
| Bucket | Under 1 year | 1–2 years | 2–3 years | 3–4 years | Over 4 years | Total |
|---|---|---|---|---|---|---|
Debt | 1990 | 2,484 | 1,836 | 1,700 | 1,830 | 9,840 |
Lease payments | 751 | 689 | 686 | 644 | 9984 (4–5 years: 627; over 5 years: 9,357) | 12,754 |
Analyst Conclusions
Management guidance (FY2026, as revised May 2026; S2; S8)
-
Revenue +4.0%–4.8%. The September 2026 update indicated about +4%, the low end.
-
Acute PPD +0.3%–0.8% (about +0.8% indicated); total PPD +1.1%–1.6% (about +1.6% indicated).
-
Normalised EBITDA margin above 18.6%.
-
Capex about R1.9bn (R566m expansionary).
-
Payout 50%–70% of adjusted HEPS.
-
Implied H2 FY2026 revenue (analyst-derived): about R14.1bn, roughly +3% on H2 FY2025 (R13.7bn), given H1 FY2026 revenue of R13.3bn and full-year growth of about 4%.
Consensus growth expectations. Detailed consensus EPS and revenue forecasts are not publicly available in verified form. Aggregator 12-month price targets cluster near R17.
Bull case
-
Margin runway continues. Margins rose in every year from FY2022 to H1 FY2026 (16.2% to 18.8%). The data/AI phase, wearables and renewable energy (about 60% from March 2027) should add further operating leverage. The digitisation track record (R705m savings on R670m invested) gives credibility.
-
Per-share compounding. With about 15% of the September 2023 share base repurchased by FY2026 (209.2m shares) and leverage at about 1.2x, buybacks plus a 4–5% dividend yield support double-digit per-share returns even with low single-digit revenue growth.
-
Mental health and adjacent growth. Mental health PPD about +8% and occupancy about 73%, with 255 beds coming. Hospital-at-home and NetcarePlus widen the addressable market beyond static scheme membership.
Bear case
-
Volume ceiling. Scheme beneficiaries grew only 0.45% in 2024. Funder solvency measures cut acute volumes in FY2026 and forced a guidance cut. Margin expansion cannot continue indefinitely without volume.
-
Policy overhang. NHI is law. Its single-fund design, if implemented, could change tariff-setting and purchasing. Competition policy limits acquisition-led growth.
-
Transition and capital-allocation risk. A founder-CEO of about 30 years is leaving. H1 FY2026 cash generation fell 20%. Net debt rose to R6.1bn because of buybacks and dividends. Valuation (about 6.9x EV/EBITDA, about 13x trailing P/E) is now above aggregator targets after a roughly 35% rerating.
Key catalysts and monitorables (next 12 months)
-
23 Nov 2026: FY2026 results, final dividend and FY2027 guidance. Watch for H2 margin delivery and cash conversion recovery.
-
1 Jan 2027: Da Costa becomes CEO. Watch strategy continuity and any capital-allocation changes.
-
Calendar 2027 scheme benefit designs and DSP network tenders.
-
Wind PPA commissioning (six hospitals from September 2026; 56 facilities from March 2027).
-
Wearables pilot outcome and rollout decision.
-
Akeso Alberlito opening (March 2027) and Montana timing (August 2027).
-
NHI litigation outcomes and any proclamation of NHI Act sections.
-
Remgro's strategy for Mediclinic SA and Life Healthcare's complementary-services expansion.
-
Continuation and pricing of buybacks, given the share price is above aggregator targets.
Analyst verdict
Netcare is a well-run, cash-generative incumbent in a structurally constrained market. The FY2021–FY2025 record shows management's ability to extract operating leverage from a near-static volume base:
-
Normalised EBITDA compounded at about 11% a year on revenue growth of about 6%.
-
Adjusted HEPS roughly doubled, from 67.4c to 137.2c.
-
ROIC improved from 7.9% to 12.6%.
These gains rest on concrete actions, not accounting. The digitisation programme has paid back its investment, energy initiatives have cut costs, and buybacks have been executed below the current price (average 1,338c to May 2026, against 1,922c in August 2026).
The constraint is volume. Medical scheme coverage is flat at about 9 million lives. Funders are tightening benefits to protect solvency. FY2026 acute PPD growth of about 0.8%, together with the May 2026 guidance cut, shows how quickly funder behaviour reaches Netcare's income statement. Future growth depends on three things: further margin gains (now from a high 18–19% base), niche capacity growth (mental health, higher-acuity beds), and new care models (hospital-at-home, NetcarePlus) that are still small.
The investment case therefore turns on durability rather than growth. Netcare should be able to sustain mid-single-digit revenue growth, modest margin gains and steady capital returns, giving low-teens per-share earnings growth while leverage stays near 1.2x. The main swing factors are policy (NHI), funder contracting, and how smoothly leadership passes from a founder-CEO to a long-serving insider. Da Costa's background in health policy and in the Akeso build-out fits the mental health and policy-engagement priorities. After a re-rating to about 13x trailing earnings and about 7x EV/EBITDA, the shares price in much of the margin story. Upside likely needs evidence of volume recovery or measurable AI-driven savings in FY2027. This assessment is for information only and is not investment advice.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Education | Source |
|---|---|---|---|---|
Dr Richard H. Friedland | Chief Executive Officer; executive director | Co-founded Netcare in 1996; has led the group for more than three decades. Retires from the Board on 31 Dec 2026. Strategic adviser on a consultancy basis from 1 Jan to 30 Jun 2027. Business Day reports he originally planned to step down in September 2024 but stayed on when the planned succession did not proceed. | — | S9; S2 |
Melanie S. Da Costa | CEO-designate from 1 Jun 2026; CEO from 1 Jan 2027. Previously Executive Director: Strategy and Health Policy. | Joined Netcare in 2006 to set up its Health Policy Unit. Led the Akeso acquisition and served as Akeso MD. Prescribed officer (FY2024). | Chartered Financial Analyst (CFA) | S9; S3 |
Keith N. Gibson | Chief Financial Officer; executive director | CFO through FY2021–H1 FY2026; supervises preparation of the financial statements | CA(SA) | S2; S3 |
T. Akaloo | Prescribed officer | — | — | S3, FY2024 |
C.E. Grindell | Prescribed officer | — | — | S3, FY2024 |
W.N. van der Merwe | Prescribed officer | — | — | S3, FY2024 |
E. Bock | Prescribed officer (part of FY2024) | — | — | S3, FY2024 |
J. du Plessis | Former prescribed officer | Resigned 30 Jun 2024; 1,164,090 Single Incentive Plan shares forfeited | — | S3, FY2024 |
C.M. Vikisi | Company Secretary | — | — | S2 |
Directors' Remuneration
| Executive | Guaranteed package | Bonus paid (for prior year) | Total cash | Grant-date fair value of deferred shares | Total incl. deferred grant |
|---|---|---|---|---|---|
R.H. Friedland (CEO) | 12,052 | 5,230 | 17,282 | 21,675 | 38,957 |
K.N. Gibson (CFO) | 7,204 | 2,562 | 9,766 | 10,620 | 20,386 |
M.S. Da Costa | 5,245 | 1,468 | 6,713 | 6,082 | 12,795 |
C.E. Grindell | 4,615 | 1,324 | 5,939 | 5,486 | 11,425 |
T. Akaloo | 4,256 | 1,057 | 5,313 | 4,380 | 9,693 |
J. du Plessis (to 30 Jun 2024) | 2,795 | 2,263 | 5,058 | 9,380 | 14,438 |
Board of Directors
| Director | Role | Notes |
|---|---|---|
Alex Maditse | Independent non-executive Chair | Lead Independent Director from 29 Jul 2024; Chair after Mark Bower retired on 30 Sep 2024 |
R.H. Friedland | Executive director (CEO) | Retiring 31 Dec 2026 |
K.N. Gibson | Executive director (CFO) | — |
L. Human | Independent non-executive | FY2024 fees R1,563k |
I. Kirk | Independent non-executive | Appointed 1 Jan 2023; CA; joined Audit Committee Jul 2024 |
B. Mathe | Independent non-executive | Appointed with effect from 1 Oct 2025, after B. Bulo (former Audit Committee Chair) resigned on 30 Sep 2025. |
N. Moholi | Independent non-executive | — |
R. Phillips | Independent non-executive | — |
L. Stephens | Independent non-executive | Appointed 1 Jan 2023; CA and chartered director; Audit and Remuneration committees |
Major Shareholders
| Holder | Stake | Basis / date | Source |
|---|---|---|---|
Government Employees Pension Fund (via Public Investment Corporation) | 22.58% (beneficial) | 30 Sep 2024, net of treasury shares | S3 |
Public Investment Corporation (as investment manager) | 17.18% | 30 Sep 2024 | S3 |
Public Investment Corporation | 19.67% | 2 Jul 2025 (Profile's Handbook) | S17 |
Fairtree Asset Management | 7.55% | 30 Sep 2024 | S3 |
Templeton Asset Management | 6.58% | 30 Sep 2024 | S3 |
Ninety One SA | 5.06% | 30 Sep 2024 | S3 |
Competitive Landscape
Key Competitors
| # | Competitor | Segment(s) competed | Ownership | Latest scale data | Source |
|---|---|---|---|---|---|
| 1 | Life Healthcare Group (JSE: LHC) | Acute hospitals, mental health, renal (incl. former Fresenius Medical Care SA renal business), complementary services | Listed | FY2025 (Sep YE): revenue from continuing operations R25.1bn (+6%); acute revenue R21.3bn; normalised EBITDA R3.8bn (+4.7%); NEPS 100.3c. H1 FY2026: revenue R12.42bn (+2.4%); normalised EBITDA R1.96bn (+5.2%). | S12 |
| 2 | Mediclinic Southern Africa | Acute hospitals, day clinics, mental health, sub-acute; ER24 (EMS); Intercare (primary care) | 100% Remgro since 1 Jul 2026 | About 50 hospitals, 8,991 beds, 21,400+ employees (SA and Namibia). Purchase consideration US$947m. | S13 |
| 3 | National Hospital Network (NHN) | Acute (association of independent hospitals contracting collectively) | Members independently owned | — | — |
| 4 | Lenmed Health | Acute hospitals | Private | — | — |
| 5 | Busamed | Acute hospitals | Private | — | — |
| 6 | Clinix Health Group | Acute hospitals (township and peri-urban) | Private | — | — |
| 7 | JMH Group | Acute hospitals (KwaZulu-Natal) | Private | — | — |
| 8 | Melomed | Acute hospitals (Western Cape) | Private | — | — |
| 9 | ER24 (Mediclinic) | Emergency medical services vs Netcare 911 | Remgro | — | S13 |
| 10 | Intercare (Mediclinic) | Primary care / day hospitals vs Medicross | Remgro | — | S13 |
| 11 | Life Healthcare mental health and renal units | Mental health vs Akeso; renal vs NRC | Listed | Complementary services revenue R2.6bn (+24.7%, FY2025) | S12 |
| 12 | Public sector hospitals | Uninsured market (relevant to NetcarePlus, NHI) | State | — | — |
Peer Comparison
| Group | Share of private beds (%) | Share of private admissions (%) |
|---|---|---|
Netcare | 31.0 | 33.0 |
Mediclinic | 26.8 | 28.6 |
Life Healthcare | 25.3 | 28.5 |
Three groups combined | 83 | 87 |
Peer Comparison FY2025
| Metric | Netcare (FY2025, Sep YE) | Life Healthcare (FY2025, Sep YE) | Mediclinic Holdings (group, FY to Mar 2026) |
|---|---|---|---|
Revenue | R26.3bn | R25.1bn (continuing operations) | US$5,356m adjusted (includes Swiss operations) |
Revenue growth | +4.5% | +6.0% | +11% (+5% in constant currency) |
Normalised EBITDA | R4.91bn | R3.8bn | US$842m adjusted |
EBITDA margin | 18.6% | about 15.1% (analyst-derived) | 15.7% |
Earnings per share growth | Adjusted HEPS +20.7% | NEPS +10.1% | — |



